May 18, 2026 a 09:00 am
COR: Analysts Ratings - Cencora, Inc.
Cencora, Inc., formerly AmerisourceBergen Corporation, demonstrates a notable position in the pharmaceutical distribution landscape. As a company spanning both domestic and international markets, its strengths lie in healthcare solutions and distribution channels. The latest analysis includes a substantial number of Buy ratings, reflecting confidence in the company's growth potential despite competitive challenges. This balance of ratings suggests a stable market position.
Historical Stock Grades
| Rating Type | Number | Score |
|---|---|---|
| Strong Buy | 4 | |
| Buy | 8 | |
| Hold | 3 | |
| Sell | 0 | |
| Strong Sell | 0 |
Sentiment Development
Over recent months, Cencora, Inc.'s sentiment has shown a notable trend of increasing confidence among analysts. The number of Strong Buy ratings has increased from previous lows, indicating growing positive sentiment. Meanwhile, Buy recommendations remain steady, suggesting consistent belief in the company's market strategies.
- The number of Buy recommendations has remained fairly stable.
- Strong Buy ratings have seen an uptick in the latest period.
- Hold ratings have shown a decline, emphasizing reduced caution.
Percentage Trends
Examination of the distribution of analyst ratings reveals shifts in sentiment, most notably a gradual enhancement of Strong Buy and Buy ratings. A deeper analysis shows:
- The percentage of Strong Buys has improved, indicating increased confidence.
- Buy ratings continue to dominate, highlighting ongoing trust in Cencora's operations.
- Strong Sell and Sell ratings remain absent, underscoring a positive market perspective.
Latest Analyst Recommendations
Recent analyst activities around Cencora, Inc. are characterized by a series of maintained ratings. Analysts predominantly continue to hold their previous ratings, reflecting a stable outlook.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-05-11 | Overweight | Overweight | Wells Fargo |
| 2026-05-07 | Buy | Buy | Citigroup |
| 2026-05-07 | Outperform | Outperform | Baird |
| 2026-05-07 | Buy | Buy | UBS |
| 2026-05-07 | Outperform | Outperform | Evercore ISI Group |
Analyst Recommendations with Change of Opinion
Over the recent periods, some analysts have shifted their stance on Cencora, Inc., signaling a dynamic evaluation process. Upgrades have been more prevalent, indicating improved perceptions of value.
| Date | New Recommendation | Last Recommendation | Publisher |
|---|---|---|---|
| 2026-01-29 | Overweight | Equal Weight | Morgan Stanley |
| 2026-01-22 | Buy | Hold | Jefferies |
| 2025-06-03 | Overweight | Equal Weight | Wells Fargo |
| 2022-10-10 | Buy | Neutral | B of A Securities |
| 2022-07-10 | In Line | Outperform | Evercore ISI Group |
Interpretation
The data on Cencora, Inc. suggests cautious optimism from analysts. The small but notable increase in Strong Buy and Buy recommendations illustrates growing confidence in the company's strategic direction and market performance. However, stability in ratings indicates a balanced recognition of both potential risks and rewards, with few aggressive changes in sentiment. The absence of Strong Sell ratings conveys a general sense of security, though ongoing watchfulness is advised as the landscape evolves.
Conclusion
In summary, Cencora, Inc. is viewed positively by market analysts, with reassurances in its expanding healthcare solutions and stable growth. While there are incremental upgrades, the consistent recommendations hint at sustained market confidence. However, the potential for external industry pressures means that a vigilant market view is warranted. The increasing positivity signals opportunities, though a balanced approach remains crucial in navigating any unforeseen challenges. Overall, Cencora presents a promising outlook aligned with a moderate risk-reward profile.
Smart Data Insight
Master the Perfect Entry & Exit for this Stock
Don't leave your profits to chance. Historically, this stock follows specific seasonal patterns that institutional traders use to maximize returns.
- ✅ Identify the "Golden Buying Window"
- ✅ Avoid high-risk correction cycles
- ✅ Backtested data from the last 20+ years